Attended by specialists in the digestive disease area, the 9th Chinese H. pylori and Digestive Diseases Forum was held in Guangzhou on August 8-9, 2014. This conference provided a platform for world and national leading experts in the digestive disease area to present research, exchange ideas and discuss collaborative opportunities. TenNor’s Founder and CEO, Dr. Zhenkun Ma was invited to speak at the Forum and presented a seminar titled “New Drugs for HP Eradication – Need and Reality.” The talk was well received. Professor Hu Fulian, Chairwoman of the conference commented: "This speech is one of the highlights of the Forum. It is totally consistent with the general theme of the conference: Cooperation, Exploration, Innovation and Truth-seeking." Vice President Erdong Hua and Investment Manager Xuepeng Guan from Frontline Bioventures attended this Forum.

About TenNor Therapeutics

TenNor Therapeutics (6872.HK), incorporated in 2013, is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative programs, including two Core Products, namely: rifasutenizol (TNP-2198), a multi-targeted conjugated new molecular entity (“NME”) candidate for the treatment of Helicobacter pylori infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and Clostridioides difficile (C. difficile) infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as prosthetic joint infection, left ventricular assist device infection and catheter-related bloodstream infection).

For more information, please visit: www.tennortherapeutics.com